Document:

Document

Exhibit 10.15
RESTRICTED STOCK UNIT AGREEMENT
TO EMPLOYEES

This Restricted Stock Unit Agreement (this “Agreement”), dated as of [DATE] (the “Grant Date”), is made between Guild Holdings Company (the “Company”), and [NAME] (the “Participant”).

W I T N E S S E T H

The Guild Holdings Company 2020 Omnibus Incentive Plan (the “Plan”) (any and all capitalized terms used in this Agreement and not defined herein shall have the meanings ascribed to them in the Plan) provides for the grant of Restricted Stock Units. In consideration of the mutual promises and covenants made herein and the mutual benefits to be derived herefrom, the parties hereto agree as follows:

1.Grant and Vesting of Restricted Stock Units.

(a)Grant of Restricted Stock Units. Subject to the terms and conditions set forth in the restricted stock unit grant notice (“Grant Notice”), in this Agreement, and in the Plan, the Company hereby grants to the Participant, as of the Grant Date, [NUMBER] restricted stock units (the “Restricted Stock Units”), each with respect to one Share. The Restricted Stock Units shall vest in accordance with Section 1(b) of this Agreement. As a condition to receiving the Restricted Stock Units, the Participant hereby agrees to comply with the restrictive covenants set forth in Annex A to this Agreement (the “Restrictive Covenants”).

(b)Vesting Schedule. Subject to the terms and conditions of this Agreement and the provisions of the Plan, the Restricted Stock Units shall vest (such period during which a Restricted Stock Unit is unvested, the “Vesting Period” with respect to such unit) as provided in the Grant Notice.

(c)Termination of Service. Except as otherwise provided in Section 1(c)(i) or Section 1(c)(ii), in the event that the Participant incurs a Termination of Service during the Vesting Period for any reason, all unvested Restricted Stock Units shall be forfeited by the Participant effective immediately upon such Termination of Service and shall cease to be eligible for vesting hereunder.

(i)In the event that the Participant incurs a Termination of Service during the Vesting Period due to the Participant’s death or Disability, all remaining outstanding and unvested Restricted Stock Units granted hereunder shall immediately vest.

(ii)In the event of a Change in Control, the provisions of Section 10 of the Plan shall apply to the Restricted Stock Units. For purposes of applying Section 10(d) of the

Plan to the Restricted Stock Units, the Participant’s Termination from Service due to a resignation for Good Reason that occurs within 24 months following a Change in Control shall have the same effect as a Termination of Service without Cause (excluding a Termination of Service due to the Participant’s death or Disability) that occurs within 24 months following a Change in Control, as described in Section 10(d) of the Plan. For purposes of this Agreement, “Good Reason” means the occurrence of any of the following without the Participant’s prior written consent: (A) a material diminution in the Participant’s position, authority, duties or responsibilities from those in effect immediately prior to the Change in Control, (B) a reduction in the Participant’s annual base salary from that in effect immediately prior to the Change in Control, (C) a material reduction in the Participant’s target annual cash incentive compensation opportunity from that in effect immediately prior to the Change in Control, (D) a material reduction in the Participant’s annual long-term incentive compensation opportunity (excluding IPO-related awards) from that in effect immediately prior to the Change in Control, or (E) a change in the geographic location of the Participant’s principal place of employment of more than 50 miles from the geographic location of the Participant’s principal place of employment as of immediately prior to the Change in Control. In order to invoke a resignation for Good Reason, the Participant shall provide written notice to the Company of the existence of one or more of the conditions described in clauses (A) through (E) within 90 days of the initial existence of such condition or conditions, specifying in reasonable detail the conditions constituting Good Reason, and the Company shall have 30 days following receipt of such written notice (the “Cure Period”) during which it may remedy the condition. In the event that the Company fails to remedy the condition constituting Good Reason during the applicable Cure Period, then in order for the Participant’s termination of employment to constitute a resignation for Good Reason, it must occur, if at all, within 30 days following the earlier of (i) the end of the Cure Period or (ii) the date the Company provides written notice to the Participant that it does not intend to cure such condition.

(d)Forfeiture and Clawback.

(i)Notwithstanding any other provision hereof, in the event that the Participant violates any of the Restrictive Covenants or any other restrictive covenants set forth in any other agreement between the Participant and the Company, the Restricted Stock Units, to the extent unvested, shall be immediately forfeited. Such forfeiture is in addition to, and not in lieu of, the other remedies available to the Company as described in Annex A (or any other agreement between the Participant and the Company that contains the applicable restrictive covenants).

(ii)Notwithstanding anything to the contrary contained herein, (A) in the event that the Participant violates any of the Restrictive Covenants or any other restrictive covenants set forth in any other agreement between the Participant and the Company or (B) to the extent permitted or required by applicable law and Applicable Exchange rules or by any applicable Company policy or arrangement as in effect from time to time, the Company may (or to the extent required, shall) (1) cause the Restricted Stock Units, to the extent unvested, to be immediately forfeited and/or (2) require the Participant to deliver to the Company the Shares previously issued to the Participant upon settlement of the Restricted Stock Units (or, if such Shares have been sold, pay to the Company the after-tax cash proceeds realized by the Participant upon such sale). By accepting the Restricted Stock Units, the Participant agrees that

the Participant is subject to any clawback policies of the Company in effect from time to time.

2.Settlement of Units.

As soon as practicable after any Restricted Stock Unit has vested, the Company shall, subject to Section 6 of this Agreement, cause the Restricted Stock Units to be settled in Shares. The obligation of the Company to deliver Shares hereunder shall be subject to all applicable laws, rules, and regulations and such approvals by governmental agencies as may be deemed appropriate by the Committee, including such actions as Company counsel shall deem necessary or appropriate to comply with relevant securities laws and regulations. The Company may require that the Participant represent that the Participant is acquiring Shares for the Participant’s own account, or such other representation as the Committee deems appropriate.

3.Nontransferability.

The Restricted Stock Units shall not be transferable by the Participant by means of sale, assignment, exchange, encumbrance, pledge, hedge or otherwise.

4.Grant Subject to Plan Provisions.

This grant is made pursuant to the Plan, the terms of which are incorporated herein by reference, and in all respects shall be interpreted in accordance with the Plan. This grant is subject to the provisions of the Plan and to interpretations, regulations and determinations concerning the Plan established from time to time by the Committee in accordance with the provisions of the Plan, including, but not limited to, provisions pertaining to (a) rights and obligations with respect to withholding taxes, (b) the registration, qualification or listing of the Shares, (c) capital or other changes of the Company and (d) other requirements of applicable law. The Committee shall have the authority to interpret and construe this Agreement pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder. In the event of any conflict between this Agreement and the terms of the Plan, the terms of the Plan shall control.

5.No Shareholder Rights.

The Participant shall not be entitled to any rights of a stockholder with respect to the Restricted Stock Units (including, without limitation, any voting rights or rights with respect to dividends). Notwithstanding the foregoing, upon the Company’s payment of an ordinary cash dividend with respect to Shares, the number of Restricted Stock Units shall be increased by dividing the amount of dividend the Participant would have received had the Participant owned a number of shares of Common Stock equal to the number of Restricted Stock Units then credited to the Participant’s account by the Fair Market Value of a share of Common Stock on the last trading day before the date of the dividend payment. The units so credited will be subject to the same restrictions applicable to the underlying Restricted Stock Units and the other terms and conditions applicable to the underlying Restricted Stock Units and will be settled in Shares at the time that the underlying Restricted Stock Units are settled, if at all.

6.Taxes and Withholding.

No later than the date as of which an amount first becomes includible in the gross income of the Participant for federal, state, local or foreign income tax purposes with respect to any Restricted Stock Units, the Participant shall pay to the Company, or make arrangements satisfactory to the Company regarding the payment of, any federal, state, local and foreign taxes that are required by applicable laws and regulations to be withheld with respect to such amount. The obligations of the Company under this Agreement shall be conditioned on compliance by the Participant with this Section 6, and the Company shall, to the extent permitted by law, have the right to deduct any such taxes from any payment otherwise due to the Participant, including deducting such amount from the delivery of shares or cash issued upon settlement of the Restricted Stock Units that gives rise to the withholding requirement. Notwithstanding the foregoing, if the Participant is an individual covered under Section 16 of the Securities Exchange Act of 1934, as amended, at the time that a taxable event occurs, then, unless otherwise determined by the Committee in advance of the taxable event, the Company’s withholding obligations with respect to such taxable event will be satisfied by the Company deducting Shares subject to the Restricted Stock Units having a Fair Market Value on the date of deduction equal to the amount required to be withheld for tax purposes (calculated using the minimum statutory withholding rate, except as otherwise approved by the Committee).

7.Effect of Agreement.

The rights and interests of the Participant under this Agreement may not be sold, assigned, encumbered or otherwise transferred except, in the event of the death of the Participant, by will or by the laws of descent and distribution. The rights and protections of the Company hereunder shall extend to any successors or assigns of the Company and to the Company’s parents, subsidiaries, and affiliates. This Agreement may be assigned by the Company without the Participant’s consent. Except as otherwise provided hereunder, this Agreement shall be binding upon and shall inure to the benefit of any successor or successors of the Company. The invalidity or enforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. Nothing in this Agreement or the Plan shall confer upon the Participant any right to continue in the employ or service of the Company or any of its affiliates or interfere in any way with the right of the Company or any such affiliates to terminate the Participant’s employment or service at any time.

8.Governing Law; Captions.

This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware, without regard to the principles of conflicts of law thereof. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect.

9.Signature in Counterparts.

This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. The parties hereto confirm that any facsimile copy of another party’s executed counterpart of this Agreement (or its signature page thereof) will be deemed to be an executed original thereof.

[Signature Page Follows.]

IN WITNESS WHEREOF, as of the date first above written, the Company has caused this Agreement to be executed on its behalf by a duly authorized officer, and the Participant has hereunto set the Participant’s hand.

GUILD HOLDINGS COMPANY

By:         Name:
Title:

[PARTICIPANT NAME]

[Signature Page to Restricted Stock Unit Agreement]

Annex A

Restrictive Covenants

As used in this Annex A, the “Company” refers to Guild Holdings Company collectively with its affiliates and subsidiaries.

1.Nondisclosure of Confidential Information.

(a)Definition of Confidential Information. As used herein, the term “Confidential Information” means the Company’s confidential and proprietary information, which includes, without limitation, information about the Company’s products and services, customers and prospective customers, the buying patterns and needs of customers and prospective customers, vendors and suppliers, pricing, quoting, costing systems, billing and collection procedures, proprietary software and the source code thereof, financial and accounting data, data processing and communications, technical data, marketing concepts and strategies, business plans, mergers and acquisitions, research and development of new or improved products and services, and general know-how regarding the business of the Company and its products and services. The Participant expressly acknowledges and agrees that Confidential Information may include, without limitation, confidential and proprietary information belonging to various third parties, such as the Company’s affiliates, vendors, agents or customers, but which has been and will be entrusted to the Company for use by the Company to conduct its business. The failure to mark or designate information as “confidential” or “proprietary” shall not prevent information that has been or will be accessed by or disclosed to the Participant from being deemed Confidential Information under this Agreement.

(b)Access. The Participant acknowledges that the Participant’s employment with the Company as a key employee necessarily has involved and/or will involve, exposure to and familiarity with, the Confidential Information.

(c)Participant’s Obligations. The Participant further acknowledges that the Confidential Information is a valuable, special and unique asset of the Company, such that the unauthorized disclosure or use by the Participant, or persons or entities outside the Company, would cause irreparable damage to the business of the Company. Accordingly, the Participant agrees that, during and after the Participant’s employment with the Company, the Participant shall not directly or indirectly disclose to any person or entity or use for any purpose or permit the exploitation, copying or summarizing of any Confidential Information of the Company, except as specifically required in the proper performance of the Participant’s duties for the Company. The Participant represents and warrants that no such disclosure or use has occurred prior to the date hereof.

(d)Trade Secret Status. The Company considers much of its Confidential Information to constitute trade secrets of the Company (“Trade Secrets”) which have independent value, provide the Company with a competitive advantage over its competitors who do not know the Trade Secrets, and are protected from unauthorized disclosure under applicable law. However, whether or not the Confidential Information constitutes Trade Secrets, the Participant acknowledges and agrees that the Confidential Information is protected from

unauthorized disclosure or use due to the Participant’s covenants under this Agreement and the Participant’s fiduciary duties as an employee of the Company.

(f)Protections. The Participant acknowledges that the Company has instituted, and will continue to institute, update, and amend policies and procedures designed to protect the confidentiality and security of the Company’s Confidential Information, including, but not limited to, policies and procedures designed by the Company to protect the status of the Company’s Trade Secrets. The Participant agrees to take all appropriate action, whether by instruction, agreement or otherwise, to ensure the protection, confidentiality and security of the Company’s Confidential Information, to protect the status of the Company’s Trade Secrets, and to satisfy the Participant’s obligations under this Agreement.

(g)Return of Documents. The Participant acknowledges and agrees that the Confidential Information is and at all times shall remain the sole and exclusive property of the Company. Upon the termination of the Participant’s employment with the Company or upon request by the Company at any time, the Participant will promptly return to the Company in good condition all of the Company property, including, without limitation, all documents, data and records of any kind, whether in hard copy or electronic form, that contain any Confidential Information or that were prepared based on Confidential Information, including any and all copies thereof, as well as all materials furnished to or acquired by the Participant during the course of the Participant’s employment with the Company. The Participant shall keep no Confidential Information in any form or medium.

2.Nonsolicitation of Customers. In order to prevent the improper use of Confidential Information and the resulting unfair competition and misappropriation of goodwill and other proprietary interests, the Participant agrees that while the Participant is employed by the Company and for a period of eighteen (18) months following the termination of the Participant’s employment for any reason whatsoever, whether such termination is voluntary or involuntary, and regardless of cause, the Participant will not, directly or indirectly, on the Participant’s own behalf or by aiding any other individual or entity, use the Company’s Trade Secrets and Confidential Information, including, without limitation, the identity of the Company’s customers, or prospective customers, the identity of the Company’s employees, contractors or consultants, special needs, job orders, preferences, transaction histories, contacts, characteristics, agreements and prices, to call on, solicit, divert, serve, accept or receive business from any of the Company’s customers (with whom the Participant had personal contact and did business during the twelve-
(12) month period immediately prior to the termination of the Participant’s employment) for the purpose of providing said customers with products and/or services of the type or character typically provided to such customers by the Company.

3.Nonsolicitation of Employees. In order to prevent the improper use of Confidential Information and the resulting unfair competition and misappropriation of goodwill and other proprietary interests, the Participant agrees that while the Participant is employed by the Company and for a period of eighteen (18) months following the termination of the Participant’s employment for any reason whatsoever, whether such termination is voluntary or involuntary, and regardless of cause, the Participant will not, directly or indirectly, on the Participant’s own behalf or by aiding any other individual or entity, employ or solicit for employment any employee of the Company with whom employee worked and had personal contact while

employed by the Company, except to the extent such employment or solicitation for employment is for a business that is not competitive with the business, products or services offered or provided by the Company and cannot adversely affect the Company’s relationship or volume of business with its customers.

4.Noncompetition. In order to prevent the improper use of Confidential Information and the resulting unfair competition and misappropriation of goodwill and other proprietary interests, the Participant agrees that while the Participant is employed by the Company, the Participant shall not, directly or indirectly, be involved in, or prepare to be involved in, any business activity that is directly or indirectly in competition with any business activity of the Company or any product or service offered, sold or solicited by the Company.

5.Reasonable Restrictions.

(a)Applicable to any Status. The Participant acknowledges and agrees that the post- employment obligations of this Agreement shall be applicable to the Participant regardless of whether the Participant engages in the restricted activity as an individual or as a sole proprietor, stockholder, partner, member, officer, director, employee, agent, consultant, or independent contractor of any other entity.

(b)Reasonable Restrictions. In signing this Agreement, the Participant is fully aware of the restrictions that this Agreement places upon the Participant’s future employment or contractual opportunities with someone other than the Company. However, the Participant understands and agrees that the Participant’s employment by the Company, the Participant’s privileged position with the Company, and the Participant’s access to Confidential Information make such restrictions both necessary and reasonable. The Participant acknowledges and agrees that the restrictions hereby imposed constitute reasonable protections of the legitimate business interests of the Company and that they will not unduly restrict the Participant’s opportunity to earn a reasonable living following the termination of the Participant’s employment.

7.Enforcement. The Participant acknowledges and agrees that, by reason of the sensitive nature of the Confidential Information and Trade Secrets referred to in this Agreement, a breach of any of the promises or agreements contained herein will result in irreparable and continuing damage to the Company for which there may not be an adequate remedy at law. If the Participant violates any of the terms of this Agreement, all the Company obligations under this Agreement shall cease without relieving the Participant of his or her continuing obligations hereunder. The Participant acknowledges and agrees that, in addition to the recovery of damages and any other legal relief to which the Company may be entitled in the event of the Participant’s violation of this Agreement, the Company shall also be entitled to equitable relief, including such injunctive relief as may be necessary to protect the interests of the Company in such Confidential Information and Trade Secrets, and as may be necessary to specifically enforce this Agreement.

8.Reformation and Severability. The Participant and the Company intend and agree that if a court of competent jurisdiction determines that the scope of any provision set forth in this Annex A is too broad to be enforced as written, the court should reform such provision(s) to such narrower scope as it determines to be enforceable. The Participant and the Company further agree that if any provision of this Agreement is determined to be unenforceable for any reason,

and such provision cannot be reformed by the court as anticipated above, such provision shall be deemed separate and severable and the unenforceability of any such provision shall not invalidate or render unenforceable any of the remaining provisions hereof.Exhibit 4.2

    

    

    DESCRIPTION OF SECURITIES

    

    

    The following description of the securities of Healthcare Services Acquisition Corporation (the “company,” “we” or “us”) is a summary and does not purport to be complete. It is subject to and qualified in its entirety
      by reference to the Company's amended and restated certificate of incorporation, bylaws and the Company's warrant agreement with Continental Stock Transfer & Trust Company, as warrant agent (the “warrant agreement”), each of which is filed as an
      exhibit to the Annual Report on Form 10-K/A of which this Exhibit 4.2 is a part. We encourage you to read such documents for additional information.

    

    

    Pursuant to our amended and restated certificate of incorporation, our authorized capital stock consists of 100,000,000 shares of Class A common stock, $0.0001 par value, 10,000,000 shares of Class B common stock,
      $0.0001 par value, and 1,000,000 shares of undesignated preferred stock, $0.0001 par value.

    

    

    UNITS

    

    

    Each unit consists of one share of Class A common stock and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of our Class A common stock at a price of $11.50 per
      share, subject to adjustment. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of Class A common stock. This means that only a whole warrant may be exercised at any given time by a
      warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

    

    

    COMMON STOCK

    

    

    Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. Other than as described below, holders of the Class A common stock and holders of the Class B
      common stock vote together as a single class on all matters submitted to a vote of our stockholders, including any vote in connection with our initial business combination, except as required by law. Unless specified in our amended and restated
      certificate of incorporation or bylaws, or as required by applicable provisions of the Delaware General Corporation Law, as amended (the “DGCL”) or applicable stock exchange rules, the affirmative vote of a majority of our shares of common stock that
      are voted is required to approve any such matter voted on by our stockholders. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the election of
      directors can elect all of the directors. Our stockholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Prior to our initial business combination, only holders
      of our Class B common stock will have the right to vote on the election of directors. Holders of our public shares will not be entitled to vote on the election of directors during such time. In addition, prior to the completion of an initial business
      combination, holders of a majority of our Class B common stock may remove a member of the board of directors for any reason.

    

    

    
      
        

    

    Because our amended and restated certificate of incorporation authorizes the issuance of up to only 100,000,000 shares of Class A common stock, if we were to enter into an initial business
      combination, we may (depending on the terms of such an initial business combination) be required to increase the number of shares of Class A common stock which we are authorized to issue at the same time as our stockholder vote on the initial
      business combination to the extent we seek stockholder approval in connection with our initial business combination.

    

    

    In accordance with the corporate governance requirements of the Nasdaq Stock Market (“Nasdaq”), we are not required to hold an annual meeting until one year after our first fiscal year end following
      our listing on Nasdaq. Under Section 211(b) of the DGCL, we are, however, required to hold an annual meeting of stockholders for the purposes of electing directors in accordance with our bylaws, unless such election is made by written consent in lieu
      of such a meeting. We may not hold an annual meeting of stockholders to elect new directors prior to the consummation of our initial business combination, and thus we may not be in compliance with Section 211(b) of the DGCL, which requires an annual
      meeting. Therefore, if our stockholders want us to hold an annual meeting prior to the consummation of our initial business combination, they may attempt to force us to hold one by submitting an application to the Delaware Court of Chancery in
      accordance with Section 211(c) of the DGCL.

    

    

    We will provide holders of our Class A common stock (our “public stockholders”) with the opportunity to redeem all or a portion of their public shares upon (i) the completion of our initial business
      combination or (ii) a stockholder vote to approve an amendment to our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or
      to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or (B) with respect to any other provision relating to stockholders’ rights or pre-initial
      business combination activity. Such redemptions, if any, will be made at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account as of two business days prior to the event triggering the right to redeem,
      including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes, divided by the number of then outstanding public shares, subject to the limitations described herein. The
      per-share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commission we will pay to the underwriter of our initial public offering. Our sponsor and each of our officers and
      directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to any founder shares and any public shares held by them in connection with the completion of our initial
      business combination, or a stockholder vote to approve an amendment to our amended and restated certificate of incorporation, as described above. Unlike many blank check companies that hold stockholder votes and conduct proxy solicitations in
      conjunction with their initial business combinations and provide for related redemptions of public shares for cash upon completion of such initial business combinations even when a vote is not required by law, if a stockholder vote is not required by
      law and we do not decide to hold a stockholder vote for business or other reasons, we will, pursuant to our amended and restated certificate of incorporation, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange
      Commission (“SEC”), and file tender offer documents with the SEC prior to completing our initial business combination. Our amended and restated certificate of incorporation requires these tender offer documents to contain substantially the same
      financial and other information about the initial business combination and the redemption rights as is required under the SEC’s proxy rules. If, however, a stockholder approval of the transaction is required by law, or we decide to obtain stockholder
      approval for business or other reasons, we will, like many blank check companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek stockholder approval,
      we will complete our initial business combination only if a majority of the outstanding shares of common stock voted are voted in favor of the initial business combination. A quorum for such meeting will consist of the holders present in person or by
      proxy of shares of outstanding capital stock of the company representing a majority of the voting power of all outstanding shares of capital stock of the company entitled to vote at such meeting.

    

    

    
      
        

    

    However, the participation of our sponsor, officers, directors, advisors or their affiliates in privately-negotiated transactions, if any, could result in the approval of our initial business
      combination even if a majority of our public stockholders vote, or indicate their intention to vote, against such business combination. For purposes of seeking approval of the majority of our outstanding shares of common stock voted, non-votes will
      have no effect on the approval of our initial business combination once a quorum is obtained. We intend to give approximately 30 days (but not less than 10 days nor more than 60 days) prior written notice of any such meeting, if required, at which a
      vote shall be taken to approve our initial business combination. These quorum and voting thresholds, and the voting agreements of our initial stockholders, may make it more likely that we will consummate our initial business combination.

    

    

    If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our
      amended and restated certificate of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of
      the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the shares of common stock sold in our initial public offering, which we refer to as
      the “Excess Shares.” However, we will not restrict our stockholders’ ability to vote all of their shares (including Excess Shares) for or against our initial business combination. Our stockholders’ inability to redeem the Excess Shares will reduce
      their influence over our ability to complete our initial business combination, and such stockholders could suffer a material loss in their investment if they sell such Excess Shares on the open market. Additionally, such stockholders will not receive
      redemption distributions with respect to the Excess Shares if we complete the initial business combination. As a result, such stockholders will continue to hold that number of shares exceeding 15% and, in order to dispose such shares would be
      required to sell their stock in open market transactions, potentially at a loss.

    

    

    If we seek stockholder approval in connection with our initial business combination, our sponsor and each of our officers and directors have agreed to vote their founder shares and any public shares
      purchased during or after our initial public offering (including in open market and privately negotiated transactions) in favor of our initial business combination. Additionally, each public stockholder may elect to redeem its public shares
      irrespective of whether they vote for or against the proposed transaction (subject to the limitation described in the preceding paragraph).

    

    

    
      
        

    

    Pursuant to our amended and restated certificate of incorporation, if we do not complete our initial business combination within 24 months from the closing of our initial public offering or during
      any extended time that we have to consummate a business combination beyond 24 months as a result of a stockholder vote to amend our amended and restated certificate of incorporation (an “Extension Period”) we will (i) cease all operations except for
      the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter subject to lawfully available funds therefor, redeem the public shares at a per-share price, payable in cash, equal to the aggregate
      amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes (less up to $100,000 of interest to pay dissolution expenses),
      divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law,
      and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide
      for claims of creditors and the requirements of other applicable law.

    

    

    Our sponsor and each of our officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their rights to liquidating distributions from the trust
      account with respect to any founder shares held by them if we fail to complete our initial business combination within 24 months from the closing of our initial public offering or any Extension Period. However, our sponsor or any of our officers or
      directors are entitled to liquidating distributions from the trust account with respect to any public shares they acquire after our initial public offering if we fail to complete our initial business combination within the prescribed time period.

    

    

    In the event of a liquidation, dissolution or winding up of the company after an initial business combination, our stockholders are entitled to share ratably in all assets remaining available for
      distribution to them after payment of liabilities and after provision is made for each class of stock, if any, having preference over the common stock. Our stockholders have no preemptive or other subscription rights. There are no sinking fund
      provisions applicable to the common stock, except that we will provide our stockholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the trust account, upon the
      completion of our initial business combination, subject to the limitations described herein.

    

    

    
      
        

    

    FOUNDER SHARES

    

    

    The shares of Class B common stock (“founder shares”) are identical to the shares of Class A common stock and holders of founder shares have the same stockholder rights as public stockholders, except
      that (i) the founder shares are subject to certain transfer restrictions, as described in more detail below, (ii) our sponsor and each of our officers and directors have entered into a letter agreement with us, pursuant to which they have agreed (A)
      to waive their redemption rights with respect to any founder shares and any public shares held by them in connection with the completion of our initial business combination, (B) to waive their redemption rights with respect to their founder shares
      and public shares in connection with a stockholder vote to approve an amendment to our amended and restated certificate of incorporation (x) to modify the substance or timing of our obligation to allow redemption in connection with our initial
      business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or during any Extension Period or (y) with respect to any other
      provision relating to stockholders’ rights or pre-initial business combination activity and (C) to waive their rights to liquidating distributions from the trust account with respect to any founder shares held by them if we fail to complete our
      initial business combination within 24 months from the closing of our initial public offering or during any Extension Period, although they will be entitled to liquidating distributions from the trust account with respect to any public shares they
      hold if we fail to complete our initial business combination within such time period, (iii) the Class B common stock will automatically convert into shares of our Class A common stock at the time of our initial business combination, or at any time
      prior thereto at the option of the holder, on a one-for-one basis, subject to adjustment as described herein, and (iv) are entitled to registration rights. If we submit our initial business combination to our public stockholders for a vote, our
      sponsor and each of our officers and directors have agreed pursuant to the letter agreement to vote their founder shares and any public shares held by them in favor of our initial business combination.

    

    

    The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of our initial business combination on a one-for-one basis (subject to adjustment for
      stock splits, stock dividends, reorganizations, recapitalizations and the like), and subject to further adjustment as provided herein. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed
      issued in excess of the amounts offered in our initial public offering and related to the closing of the initial business combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be
      adjusted (unless the holders of a majority of the outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon
      conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of (i) the total number of all shares of common stock outstanding upon completion of our initial public offering, plus (ii) all
      shares of Class A common stock and equity-linked securities issued or deemed issued in connection with the initial business combination (excluding any shares of Class A common stock or equity-linked securities issued, or to be issued, to any seller
      in the initial business combination, and any private placement-equivalent warrants issued to our sponsor or its affiliates upon conversion of loans made to us). We cannot determine at this time whether a majority of the holders of our Class B common
      stock at the time of any future issuance would agree to waive such adjustment to the conversion ratio. They may waive such adjustment due to (but not limited to) the following: (i) closing conditions which are part of the agreement for our initial
      business combination; (ii) negotiation with Class A stockholders on structuring an initial business combination; or (iii) negotiation with parties providing financing which would trigger the anti-dilution provisions of the Class B common stock. If
      such adjustment is not waived, the issuance would not reduce the percentage ownership of holders of our Class B common stock, but would reduce the percentage ownership of holders of our Class A common stock. If such adjustment is waived, the issuance
      would reduce the percentage ownership of holders of both classes of our common stock. Holders of founder shares may also elect to convert their shares of Class B common stock into an equal number of shares of Class A common stock, subject to
      adjustment as provided above, at any time. Securities could be “deemed issued” for purposes of the conversion rate adjustment if such shares are issuable upon the conversion or exercise of convertible securities, warrants or similar securities.

    

    

    
      
        

    

    With certain limited exceptions, the founder shares are not transferable, assignable or salable (except to our officers and directors and other persons or entities affiliated with our sponsor, each
      of whom will be subject to the same transfer restrictions) until the earlier of (A) one year after the completion of our initial business combination or (B) subsequent to our initial business combination, (x) if the last reported sale price of our
      Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our
      initial business combination, or (y) the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their shares of common
      stock for cash, securities or other property.

    

    

    Prior to our initial business combination, only holders of our Class B common stock will have the right to vote on the election of directors. Holders of our public shares will not be entitled to vote
      on the election of directors during such time. In addition, prior to the completion of an initial business combination, holders of a majority of our Class B common stock may remove a member of the board of directors for any reason. These provisions
      of our amended and restated certificate of incorporation may only be amended by a resolution passed by a majority of our Class B common stock. With respect to any other matter submitted to a vote of our stockholders, including any vote in connection
      with our initial business combination, except as required by law, holders of our Class B common stock and holders of our Class A common stock will vote together as a single class, with each share entitling the holder to one vote.

    

    

    WARRANTS

    

    

    Public Stockholders’ Warrants

    

    

    Each whole warrant entitles the registered holder to purchase one share of our Class A common stock at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing on
      the later of 12 months from the closing of our initial public offering or 30 days after the completion of our initial business combination. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of
      shares of Class A common stock. This means that only a whole warrant may be exercised at any given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The warrants will
      expire five years after the completion of our initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

    

    

    We are not obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and have no obligation to settle such warrant exercise unless a registration statement under
      the Securities Act of 1933, as amended, (the “Securities Act”), with respect to the shares of Class A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations
      described below with respect to registration. No warrant will be exercisable and we will not be obligated to issue shares of Class A common stock upon exercise of a warrant unless Class A common stock issuable upon such warrant exercise has been
      registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a
      warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will we be required to net cash settle any warrant. In the event that a registration statement is
      not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of Class A common stock underlying such unit.

    

    

    
      
        

    

    We have not registered the shares of Class A common stock issuable upon exercise of the warrants. However, we have agreed that as soon as practicable, but in no event later than 15 business days
      after the closing of our initial business combination, we will use our commercially reasonable efforts to file with the SEC a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants. We will use our
      commercially reasonable efforts to cause such registration statement to become effective within 60 business days after the closing of our initial business combination and to maintain a current prospectus relating to those shares of Class A common
      stock until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if shares of our Class A common stock are at the time of any exercise of a public warrant not listed on a national securities exchange such that
      they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9)
      of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement, but we will use our commercially reasonable efforts to register or qualify the shares under applicable blue sky laws
      to the extent an exemption is not available. If a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of our initial business
      combination, warrant holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance
      with Section 3(a)(9) of the Securities Act or another exemption. In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Class A common stock equal to the lesser of (A) the quotient obtained
      by dividing (x) the product of the number of shares of Class A common stock underlying the warrants, multiplied by the excess of the “fair market value” of our Class A common stock over the exercise price of the warrants by (y) the fair market value
      and (B) 0.361 per whole warrant. The “fair market value” as used in this paragraph shall mean the average last reported sale price of the Class A common stock for the ten trading days ending on the third trading day prior to the date on which the
      notice of exercise is received by the warrant agent. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.

    

    

    Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00. Once the warrants become exercisable, we may redeem the
      outstanding warrants (except as described herein with respect to the private placement warrants):

    

    

    	

          	•	
            in whole and not in part;

          

    

    

    	

          	•	
            at a price of $0.01 per warrant;

          

    

    

    	

          	•	
            upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and

          

    

    

    
      
        

    

    	

          	•	
            if, and only if, the last reported sale price of the Class A common stock for any 10 trading days within a 20-trading day period ending three trading days before we send the notice of redemption to the warrant
              holders (which we refer to as the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading
              “-Warrants-Public Stockholders’ Warrants-Anti-Dilution Adjustments”).

          

    

    

    We will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class A common stock issuable upon exercise of the warrants is
      then effective and a current prospectus relating to those Class A common stock is available throughout the 30-day redemption period. If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to
      register or qualify the underlying securities for sale under all applicable state securities laws.

    

    

    We have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If
      the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. Any such exercise would not be done on a
      “cashless” basis and would require the exercising warrant holder to pay the exercise price for each warrant being exercised. However, the price of the Class A common stock may fall below the $18.00 redemption trigger price (as adjusted for
      adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “-Warrants-Public Stockholders’ Warrants-Anti-Dilution Adjustments”) as well as the $11.50 (for whole shares) warrant
      exercise price after the redemption notice is issued.

    

    

    Redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00. Once the warrants become exercisable, we may redeem the
      outstanding warrants:

    

    

    	

          	•	
            in whole and not in part;

          

    

    

    	

          	•	
            at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption, provided that holders will be able to exercise their warrants on a cashless basis
              prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the “fair market value” of our Class A common stock (as defined below in the immediately following paragraph)
              except as otherwise described below;

          

    

    

    	

          	•	
            if, and only if, the Reference Value (as defined above under the heading “-Warrants-Public Stockholders’ Warrants-Redemption of warrants when the price per share of Class A common stock equals or exceeds
              $18.00”) equals or exceeds $10.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “-Warrants-Public Stockholders’ Warrants-Anti-Dilution
              Adjustments”); and

          

    

    

    	

          	•	
            if the Reference Value is less than $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “
              -Warrants-Public Stockholders’ Warrants-Anti-Dilution Adjustments”), the private placement warrants are also concurrently called for redemption on the same terms as the outstanding public warrants, as described above.

          

    

    

    
      
        

    

    Beginning on the date the notice of redemption is given until the warrants are redeemed or exercised, holders who elect to exercise their warrants may do so on a cashless basis. The numbers in the
      table below represent the number of shares of Class A common stock that a warrant holder will receive upon such cashless exercise in connection with a redemption by us pursuant to this redemption feature, based on the “fair market value” of our Class
      A common stock on the corresponding redemption date (assuming holders elect to exercise their warrants and such warrants are not redeemed for $0.10 per warrant), determined for these purposes based on the volume-weighted average price of our Class A
      common stock as reported during the ten trading days immediately following the date on which the notice of redemption is sent to the holders of warrants, and the number of months that the corresponding redemption date precedes the expiration date of
      the warrants, each as set forth in the table below. We will provide our warrant holders with the final fair market value no later than one business day after the ten-trading day period described above ends.

    

    

    Pursuant to the warrant agreement, references above to Class A common stock shall include a security other than Class A common stock into which the Class A common stock have been converted or
      exchanged for in the event we are not the surviving company in our initial business combination. The numbers in the table below will not be adjusted when determining the number of Class A common stock to be issued upon exercise of the warrants if we
      are not the surviving entity following our initial business combination.

    

    

    
      
        

    

    The share prices set forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable upon exercise of a warrant or the exercise price of a
      warrant is adjusted as set forth under the heading “-Anti-Dilution Adjustments” below. If the number of shares issuable upon exercise of a warrant is adjusted, the adjusted share prices in the column headings will equal the share prices immediately
      prior to such adjustment, multiplied by a fraction, the numerator of which is the exercise price of the warrant after such adjustment and the denominator of which is the price of the warrant immediately prior to such adjustment. In such an event, the
      number of shares in the table below shall be adjusted by multiplying such share amounts by a fraction, the numerator of which is the number of shares deliverable upon exercise of a warrant immediately prior to such adjustment and the denominator of
      which is the number of shares deliverable upon exercise of a warrant as so adjusted. If the exercise price of a warrant is adjusted, (a) in the case of an adjustment pursuant to the fifth paragraph under the heading “-Anti-dilution adjustments”
      below, the adjusted share prices in the column headings will equal the unadjusted share price multiplied by a fraction, the numerator of which is the higher of (i) the volume weighted average trading price of our Class A common stock during the 20
      trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price, the “Market Value”) and (ii) the issue price of any additional shares of our Class A common stock that we issue in
      connection with the closing of our initial business combination (the “Newly Issued Price”) as set forth under the heading “ -Anti-dilution adjustments” and the denominator of which is $10.00 and (b) in the case of an adjustment pursuant to the second
      paragraph under the heading “- Anti-dilution adjustments” below, the adjusted share prices in the column headings will equal the unadjusted share price less the decrease in the exercise price of a warrant pursuant to such exercise price adjustment.

    

    

    	
            Redemption Date

            (period to expiration of

            warrants)

          	
            ​

          	
            Fair Market Value of Class A Common Stock

          
	
            ≤10.00

          	
            ​

          	
            11.00

          	
            ​

          	
            12.00

          	
            ​

          	
            13.00

          	
            ​

          	
            14.00

          	
            ​

          	
            15.00

          	
            ​

          	
            16.00

          	
            ​

          	
            17.00

          	
            ​

          	
            ≥18.00

          
	
            60 months

          	
            ​

          	
            0.261

          	
            ​

          	
            0.281

          	
            ​

          	
            0.297

          	
            ​

          	
            0.311

          	
            ​

          	
            0.324

          	
            ​

          	
            0.337

          	
            ​

          	
            0.348

          	
            ​

          	
            0.358

          	
            ​

          	
            0.361

          
	
            57 months

          	
            ​

          	
            0.257

          	
            ​

          	
            0.277

          	
            ​

          	
            0.294

          	
            ​

          	
            0.310

          	
            ​

          	
            0.324

          	
            ​

          	
            0.337

          	
            ​

          	
            0.348

          	
            ​

          	
            0.358

          	
            ​

          	
            0.361

          
	
            54 months

          	
            ​

          	
            0.252

          	
            ​

          	
            0.272

          	
            ​

          	
            0.291

          	
            ​

          	
            0.307

          	
            ​

          	
            0.322

          	
            ​

          	
            0.335

          	
            ​

          	
            0.347

          	
            ​

          	
            0.357

          	
            ​

          	
            0.361

          
	
            51 months

          	
            ​

          	
            0.246

          	
            ​

          	
            0.268

          	
            ​

          	
            0.287

          	
            ​

          	
            0.304

          	
            ​

          	
            0.320

          	
            ​

          	
            0.333

          	
            ​

          	
            0.346

          	
            ​

          	
            0.357

          	
            ​

          	
            0.361

          
	
            48 months

          	
            ​

          	
            0.241

          	
            ​

          	
            0.263

          	
            ​

          	
            0.283

          	
            ​

          	
            0.301

          	
            ​

          	
            0.317

          	
            ​

          	
            0.332

          	
            ​

          	
            0.344

          	
            ​

          	
            0.356

          	
            ​

          	
            0.361

          
	
            45 months

          	
            ​

          	
            0.235

          	
            ​

          	
            0.258

          	
            ​

          	
            0.279

          	
            ​

          	
            0.298

          	
            ​

          	
            0.315

          	
            ​

          	
            0.330

          	
            ​

          	
            0.343

          	
            ​

          	
            0.356

          	
            ​

          	
            0.361

          
	
            42 months

          	
            ​

          	
            0.228

          	
            ​

          	
            0.252

          	
            ​

          	
            0.274

          	
            ​

          	
            0.294

          	
            ​

          	
            0.312

          	
            ​

          	
            0.328

          	
            ​

          	
            0.342

          	
            ​

          	
            0.355

          	
            ​

          	
            0.361

          
	
            39 months

          	
            ​

          	
            0.221

          	
            ​

          	
            0.246

          	
            ​

          	
            0.269

          	
            ​

          	
            0.290

          	
            ​

          	
            0.309

          	
            ​

          	
            0.325

          	
            ​

          	
            0.340

          	
            ​

          	
            0.354

          	
            ​

          	
            0.361

          
	
            36 months

          	
            ​

          	
            0.213

          	
            ​

          	
            0.239

          	
            ​

          	
            0.263

          	
            ​

          	
            0.285

          	
            ​

          	
            0.305

          	
            ​

          	
            0.323

          	
            ​

          	
            0.339

          	
            ​

          	
            0.353

          	
            ​

          	
            0.361

          
	
            33 months

          	
            ​

          	
            0.205

          	
            ​

          	
            0.232

          	
            ​

          	
            0.257

          	
            ​

          	
            0.280

          	
            ​

          	
            0.301

          	
            ​

          	
            0.320

          	
            ​

          	
            0.337

          	
            ​

          	
            0.352

          	
            ​

          	
            0.361

          
	
            30 months

          	
            ​

          	
            0.196

          	
            ​

          	
            0.224

          	
            ​

          	
            0.250

          	
            ​

          	
            0.274

          	
            ​

          	
            0.297

          	
            ​

          	
            0.316

          	
            ​

          	
            0.335

          	
            ​

          	
            0.351

          	
            ​

          	
            0.361

          
	
            27 months

          	
            ​

          	
            0.185

          	
            ​

          	
            0.214

          	
            ​

          	
            0.242

          	
            ​

          	
            0.268

          	
            ​

          	
            0.291

          	
            ​

          	
            0.313

          	
            ​

          	
            0.332

          	
            ​

          	
            0.350

          	
            ​

          	
            0.361

          
	
            24 months

          	
            ​

          	
            0.173

          	
            ​

          	
            0.204

          	
            ​

          	
            0.233

          	
            ​

          	
            0.260

          	
            ​

          	
            0.285

          	
            ​

          	
            0.308

          	
            ​

          	
            0.329

          	
            ​

          	
            0.348

          	
            ​

          	
            0.361

          
	
            21 months

          	
            ​

          	
            0.161

          	
            ​

          	
            0.193

          	
            ​

          	
            0.223

          	
            ​

          	
            0.252

          	
            ​

          	
            0.279

          	
            ​

          	
            0.304

          	
            ​

          	
            0.326

          	
            ​

          	
            0.347

          	
            ​

          	
            0.361

          
	
            18 months

          	
            ​

          	
            0.146

          	
            ​

          	
            0.179

          	
            ​

          	
            0.211

          	
            ​

          	
            0.242

          	
            ​

          	
            0.271

          	
            ​

          	
            0.298

          	
            ​

          	
            0.322

          	
            ​

          	
            0.345

          	
            ​

          	
            0.361

          
	
            15 months

          	
            ​

          	
            0.130

          	
            ​

          	
            0.164

          	
            ​

          	
            0.197

          	
            ​

          	
            0.230

          	
            ​

          	
            0.262

          	
            ​

          	
            0.291

          	
            ​

          	
            0.317

          	
            ​

          	
            0.342

          	
            ​

          	
            0.361

          
	
            12 months

          	
            ​

          	
            0.111

          	
            ​

          	
            0.146

          	
            ​

          	
            0.181

          	
            ​

          	
            0.216

          	
            ​

          	
            0.250

          	
            ​

          	
            0.282

          	
            ​

          	
            0.312

          	
            ​

          	
            0.339

          	
            ​

          	
            0.361

          
	
            9 months

          	
            ​

          	
            0.090

          	
            ​

          	
            0.125

          	
            ​

          	
            0.162

          	
            ​

          	
            0.199

          	
            ​

          	
            0.237

          	
            ​

          	
            0.272

          	
            ​

          	
            0.305

          	
            ​

          	
            0.336

          	
            ​

          	
            0.361

          
	
            6 months

          	
            ​

          	
            0.065

          	
            ​

          	
            0.099

          	
            ​

          	
            0.137

          	
            ​

          	
            0.178

          	
            ​

          	
            0.219

          	
            ​

          	
            0.259

          	
            ​

          	
            0.296

          	
            ​

          	
            0.331

          	
            ​

          	
            0.361

          
	
            3 months

          	
            ​

          	
            0.034

          	
            ​

          	
            0.065

          	
            ​

          	
            0.104

          	
            ​

          	
            0.150

          	
            ​

          	
            0.197

          	
            ​

          	
            0.243

          	
            ​

          	
            0.286

          	
            ​

          	
            0.326

          	
            ​

          	
            0.361

          
	
            0 months

          	
            ​

          	
            -

          	
            ​

          	
            -

          	
            ​

          	
            0.042

          	
            ​

          	
            0.115

          	
            ​

          	
            0.179

          	
            ​

          	
            0.233

          	
            ​

          	
            0.281

          	
            ​

          	
            0.323

          	
            ​

          	
            0.361

          

    

    

    
      
        

    

    The exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is between two values in the table or the redemption date is between
      two redemption dates in the table, the number of shares of Class A common stock to be issued for each warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the higher and lower fair market
      values and the earlier and later redemption dates, as applicable, based on a 365 or 366-day year, as applicable. For example, if the volume weighted average price of our Class A common stock as reported during the ten trading days immediately
      following the date on which the notice of redemption is sent to the holders of warrants is $11.00 per share, and at such time there are 57 months until the expiration of the warrants, holders may choose to, in connection with this redemption feature,
      exercise their warrants for 0.277 shares of Class A common stock for each whole warrant. For an example where the exact fair market value and redemption date are not as set forth in the table above, if the volume weighted average price of our Class A
      common stock as reported during the ten trading days immediately following the date on which the notice of redemption is sent to the holders of warrants is $13.50 per share, and at such time there are 38 months until the expiration of the warrants,
      holders may choose to, in connection with this redemption feature, exercise their warrants for 0.298 shares of Class A common stock for each whole warrant. In no event will the warrants be exercisable on a cashless basis in connection with this
      redemption feature for more than 0.361 shares of Class A common stock per whole warrant (subject to adjustment). Finally, as reflected in the table above, if the warrants are out of the money and about to expire, they cannot be exercised on a
      cashless basis in connection with a redemption by us pursuant to this redemption feature, since they will not be exercisable for any Class A common stock.

    

    

    This redemption feature differs from the typical warrant redemption features used in some other blank check offerings, which typically only provide for a redemption of warrants for cash (other than
      the private placement warrants) when the trading price for the Class A common stock exceeds $18.00 per share for a specified period of time. This redemption feature is structured to allow for all of the outstanding warrants to be redeemed when the
      Class A common stock is trading at or above $10.00 per share, which may be at a time when the trading price of our Class A common stock is below the exercise price of the warrants. We have established this redemption feature to provide us with the
      flexibility to redeem the warrants without the warrants having to reach the $18.00 per share threshold set forth above under “-Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00.” Holders choosing to
      exercise their warrants in connection with a redemption pursuant to this feature will, in effect, receive a number of shares for their warrants based on an option pricing model with a fixed volatility input as of the date of December 22, 2020. This
      redemption right provides us with an additional mechanism by which to redeem all of the outstanding warrants, and therefore have certainty as to our capital structure as the warrants would no longer be outstanding and would have been exercised or
      redeemed. We will be required to pay the applicable redemption price to warrant holders if we choose to exercise this redemption right and it will allow us to quickly proceed with a redemption of the warrants if we determine it is in our best
      interest to do so. As such, we would redeem the warrants in this manner when we believe it is in our best interest to update our capital structure to remove the warrants and pay the redemption price to the warrant holders.

    

    

    
      
        

    

    As stated above, we can redeem the warrants when the shares of Class A common stock are trading at a price starting at $10.00, which is below the exercise price of $11.50, because it will provide
      certainty with respect to our capital structure and cash position while providing warrant holders with the opportunity to exercise their warrants on a cashless basis for the applicable number of shares. If we choose to redeem the warrants when the
      shares of Class A common stock are trading at a price below the exercise price of the warrants, this could result in the warrant holders receiving fewer shares of Class A common stock than they would have received if they had chosen to wait to
      exercise their warrants for shares of Class A common stock if and when such shares of Class A common stock were trading at a price higher than the exercise price of $11.50.

    

    

    No fractional shares of Class A common stock will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, we will round down to the nearest
      whole number of shares of Class A common stock to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than Class A common stock pursuant to the warrant agreement (for instance, if we are not the
      surviving company in our initial business combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than Class A common stock, the Company (or surviving company) will use its
      commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants.

    

    

    Redemption procedures. A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have
      the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the warrant agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such
      other amount as a holder may specify) of the shares of Class A common stock outstanding immediately after giving effect to such exercise.

    

    

    Anti-dilution adjustments. If the number of outstanding shares of Class A common stock is increased by a stock dividend payable in shares of Class A common
      stock, or by a split-up of shares of Class A common stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Class A common stock issuable on exercise of each warrant will be
      increased in proportion to such increase in the outstanding shares of Class A common stock. A rights offering to holders of Class A common stock entitling holders to purchase shares of Class A common stock at a price less than the historical fair
      market value (as defined below) will be deemed a stock dividend of a number of shares of Class A common stock equal to the product of (i) the number of shares of Class A common stock actually sold in such rights offering (or issuable under any other
      equity securities sold in such rights offering that are convertible into or exercisable for Class A common stock) and (ii) one minus the quotient of (x) the price per share of Class A common stock paid in such rights offering divided by (y) the
      historical fair market value. For these purposes (i) if the rights offering is for securities convertible into or exercisable for Class A common stock, in determining the price payable for Class A common stock, there will be taken into account any
      consideration received for such rights, as well as any additional amount payable upon conversion or exercise and (ii) “historical fair market value” means the volume weighted average price of Class A common stock as reported during the ten trading
      day period ending on the trading day prior to the first date on which the shares of Class A common stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.

    

    

    
      
        

    

    In addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of Class A common stock on
      account of such shares of Class A common stock (or other shares of our capital stock into which the warrants are convertible), other than (a) as described above, (b) certain ordinary cash dividends (initially defined as up to $0.50 per share in a 365
      day period), (c) to satisfy the redemption rights of the holders of Class A common stock in connection with the completion of our initial business combination, (d) to satisfy the redemption rights of the holders of Class A common stock in connection
      with a stockholder vote to approve an amendment to our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100%
      of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business
      combination activity, or (e) in connection with the redemption of our public shares upon our failure to complete our initial business combination, then the warrant exercise price will be decreased, effective immediately after the effective date of
      such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of Class A common stock in respect of such event.

    

    

    If the number of outstanding shares of our Class A common stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Class A common stock or other
      similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of Class A common stock issuable on exercise of each warrant will be decreased in proportion
      to such decrease in outstanding shares of Class A common stock.

    

    

    Whenever the number of shares of Class A common stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the
      warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Class A common stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y) the
      denominator of which will be the number of shares of Class A common stock so purchasable immediately thereafter.

    

    

    In addition, if (x) we issue additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at a
      Newly Issued Price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our sponsor or its affiliates, without taking into
      account any founder shares held by our sponsor or such affiliates, as applicable, prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for
      the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the Market Value is below $9.20 per share, the exercise price of the warrants will be adjusted (to the
      nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described above under “-Redemption of warrants when the price per share of Class A common stock equals or
      exceeds $18.00” and “-Redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the
      $10.00 per share redemption trigger price described above under “-Redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value
      and the Newly Issued Price.

    

    

    
      
        

    

    In case of any reclassification or reorganization of the outstanding shares of Class A common stock (other than those described above or that solely affects the par value of such shares of Class A
      common stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of
      our outstanding shares of Class A common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved,
      the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the shares of our Class A common stock immediately theretofore purchasable
      and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a
      dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Class
      A common stock in such a transaction is payable in the form of Class A common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for
      trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be reduced as specified
      in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement) of the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the warrants when an extraordinary transaction
      occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the full potential value of the warrants in order to determine and realize the option value component of the warrant. This
      formula is to compensate the warrant holder for the loss of the option value portion of the warrant due to the requirement that the warrant holder exercise the warrant within 30 days of the event. The Black-Scholes model is an accepted pricing model
      for estimating fair market value where no quoted market price for an instrument is available.

    

    

    The warrants are issued in registered form under the warrant agreement. You should review a copy of the warrant agreement, which is filed as an exhibit to the Annual Report on Form 10-K of which this
      Exhibit 4.5 is a part, for a complete description of the terms and conditions applicable to the warrants. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct
      any defective provision, but requires the approval by the holders of at least 50% of the then outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants.

    

    

    The warrant holders do not have the rights or privileges of holders of Class A common stock and any voting rights until they exercise their warrants and receive shares of Class A common stock. After
      the issuance of shares of Class A common stock upon exercise of the warrants, each holder will be entitled to one (1) vote for each share held of record on all matters to be voted on by holders of Class A common stock.

    

    

    
      
        

    

    No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise,
      round down to the nearest whole number of shares of Class A common stock to be issued to the warrant holder.

    

    

    We have agreed that, subject to applicable law, any action, proceeding or claim against us arising out of or relating in any way to the warrant agreement will be brought and enforced in the courts of
      the State of New York or the United States District Court for the Southern District of New York, and we irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or claim. See “Risk
      Factors-Our warrant agreement will designate the courts of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be
      initiated by holders of our warrants, which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our company.” This provision applies to claims under the Securities Act but does not apply to claims under
      the Exchange Act or any claim for which the federal district courts of the United States of America are the sole and exclusive forum.

    

    

    
      
        

    

    Private Placement Warrants

    

    

    The private placement warrants (including the Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the
      completion of our initial business combination (except, among limited exceptions, to our officers and directors and other persons or entities affiliated with our sponsor or anchor investor) and they will not be redeemable by us (except as described
      above under “Description of Securities-Warrants-Public Stockholders’ Warrants-Redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00”) so long as they are held by our sponsor, anchor investor or their
      permitted transferees. Our sponsor, anchor investor and their permitted transferees, have the option to exercise the private placement warrants on a cashless basis. Except as described below, the private placement warrants have terms and provisions
      that are identical to those of the warrants being sold as part of the units in our initial public offering, including as to exercise price, exercisability and exercise period. If the private placement warrants are held by holders other than the
      sponsor, anchor investor or their permitted transferees, the private placement warrants will be redeemable by us and exercisable by the holders on the same basis as the warrants included in the units sold in our initial public offering.

    

    

    Except as described above under “-Public Stockholders’ Warrants-Redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00,” if holders of the private placement
      warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering the warrants for that number of shares of Class A common stock equal to the quotient obtained by dividing (x) the product of the number of shares
      of Class A common stock underlying the warrants, multiplied by the excess of the “fair market value” of our Class A common stock over the exercise price of the warrants by (y) the fair market value. The “fair market value” shall mean the average last
      reported sale price of the Class A common stock for the ten trading days ending on the third trading day prior to the date on which the notice of exercise is received by the warrant agent or on which the notice of redemption is sent to the holders of
      warrants, as applicable. The reason that we have agreed that these warrants will be exercisable on a cashless basis so long as they are held by the sponsor, anchor investor or their permitted transferees is because it is not known at this time
      whether they will be affiliated with us following an initial business combination. If they are affiliated with us, their ability to sell our securities in the open market will be significantly limited. We expect to have policies in place that
      prohibit insiders from selling our securities except during specific periods of time. Even during such periods of time when insiders will be permitted to sell our securities, an insider cannot trade in our securities if he or she is in possession of
      material non-public information. Accordingly, unlike public stockholders who could sell the shares of Class A common stock issuable upon exercise of the warrants freely in the open market, the insiders could be significantly restricted from doing so.
      As a result, we believe that allowing the holders to exercise such warrants on a cashless basis is appropriate.

    

    

    In order to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not
      obligated to, loan us funds as may be required. Up to $2,000,000 of such loans may be convertible into warrants at a price of $1.00 per warrant at the option of the lender. Such warrants would be identical to the private placement warrants, including
      as to exercise price, exercisability and exercise period. The terms of such working capital loans, if any, have not been determined and no written agreements exist with respect to such loans.

    

    

    
      
        

    

    Our sponsor and our anchor investor have agreed not to transfer, assign or sell any of the private placement warrants (including the Class A common stock issuable upon exercise of any of these
      warrants) until the date that is 30 days after the date we complete our initial business combination, except that, among other limited exceptions, made to our officers and directors and other persons or entities affiliated with our sponsor or our
      anchor investor.

    

    

    OUR TRANSFER AGENT AND WARRANT AGENT

    

    

    The transfer agent for our common stock and warrant agent for our warrants is Continental Stock Transfer & Trust Company. We have agreed to indemnify Continental Stock Transfer & Trust
      Company in its roles as transfer agent and warrant agent, its agents and each of its stockholders, directors, officers and employees against all claims and losses that may arise out of acts performed or omitted for its activities in that capacity,
      except for any liability due to any gross negligence, willful misconduct or bad faith of the indemnified person or entity.

    

    

    
      
        

    

    OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

    

    

    Our amended and restated certificate of incorporation contains certain requirements and restrictions that will apply to us until the completion of our initial business combination. These provisions
      cannot be amended without the approval of the holders of 65% of our common stock. Our initial stockholders, will participate in any vote to amend our amended and restated certificate of incorporation and will have the discretion to vote in any manner
      they choose. Specifically, our amended and restated certificate of incorporation provides, among other things, that:

    

    

    	

          	•	
            if we do not complete our initial business combination within 24 months from the closing of our initial public offering or during any Extension Period, we will (i) cease all operations except for the purpose of
              winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter subject to lawfully available funds therefor, redeem 100% of the public shares, at a per-share price, payable in cash, equal to the aggregate
              amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes (less up to $100,000 of interest to pay dissolution
              expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to
              applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under
              Delaware law to provide for claims of creditors and the requirements of other applicable law;

          

    

    

    	

          	•	
            prior to or in connection with our initial business combination, we may not issue additional shares of capital stock that would entitle the holders thereof to (i) receive funds from the trust account or (ii)
              vote on our initial business combination;

          

    

    

    	

          	•	
            Although we do not intend to enter into an initial business combination with a target business that is affiliated with our sponsor, directors or officers, we are not prohibited from doing so. In the event we
              enter into such a transaction, we, or a committee of independent directors, will, to the extent required by applicable law or our board of directors, obtain an opinion from an independent investment banking firm or an independent accounting
              firm that such an initial business combination is fair to our company from a financial point of view;

          

    

    

    	

          	•	
            If a stockholder vote on our initial business combination is not required by law and we do not decide to hold a stockholder vote for business or other reasons, we will offer to redeem our public shares pursuant
              to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about our
              initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act; whether or not we maintain our registration under the our Exchange Act or our listing on Nasdaq, we will provide our public
              stockholders with the opportunity to redeem their public shares by one of the two methods listed above;

          

    

    

    	

          	•	
            Our initial business combination will be approved by a majority of our independent directors;

          

    

    

    
      
        

    

    	

          	•	
            Our initial business combination must occur with one or more businesses that together have an aggregate fair market value of at least 80% of the net assets held in the trust account (excluding the deferred
              underwriting fees and taxes payable) at the time of our signing a definitive agreement in connection with our initial business combination;

          

    

    

    	

          	•	
            If our stockholders approve an amendment to our amended and restated certificate of incorporation (i) to modify the substance or timing of our obligation to allow redemption in connection with our initial
              business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or (ii) with respect to any other provision relating to
              stockholders’ rights or pre-business combination activity, we will provide our public stockholders with the opportunity to redeem all or a portion of their shares of Class A common stock upon such approval at a per-share price, payable in
              cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes, divided by the number of then
              outstanding public shares; and

          

    

    

    
      
        

    

    	

          	•	
            We will not effectuate our initial business combination with another blank check company or a similar company with nominal operations.

          

    

    

    In addition, our amended and restated certificate of incorporation provides that under no circumstances will we redeem our public shares in an amount that would cause our net tangible assets to be
      less than $5,000,001 upon consummation of our initial business combination and after payment of deferred underwriting commissions.

    

    

    CERTAIN ANTI-TAKEOVER PROVISIONS OF DELAWARE LAW AND OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AND BYLAWS

    

    

    Our amended and restated certificate of incorporation provides that we are not subject to Section 203 of the DGCL. However, our amended and restated certificate of incorporation contains similar
      provisions providing that we may not engage in certain “business combinations” with any “interested stockholder” for a three-year period following the time that the stockholder became an interested stockholder, unless:

    

    

    	

          	•	
            prior to such time, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

          

    

    

    	

          	•	
            upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the
              transaction commenced, excluding certain shares; or

          

    

    

    	

          	•	
            at or subsequent to that time, the business combination is approved by our board of directors and by the affirmative vote of holders of at least 662/3% of the outstanding voting stock that is not owned by the
              interested stockholder.

          

    

    

    Generally, a “business combination” includes a merger, asset or stock sale or certain other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions,
      an “interested stockholder” is a person who, together with that person’s affiliates and associates, owns, or within the previous three years owned, 15% or more of our voting stock.

    

    

    Under certain circumstances, this provision will make it more difficult for a person who would be an “interested stockholder” to effect various business combinations with a corporation for a
      three-year period. This provision may encourage companies interested in acquiring our company to negotiate in advance with our board of directors because the stockholder approval requirement would be avoided if our board of directors approves either
      the business combination or the transaction which results in the stockholder becoming an interested stockholder. These provisions also may have the effect of preventing changes in our board of directors and may make it more difficult to accomplish
      transactions which stockholders may otherwise deem to be in their best interests.

    

    

    Our amended and restated certificate of incorporation provides that the sponsor, its members and its other affiliates, any of its respective direct or indirect transferees who hold at least 15% of
      our outstanding common stock after such transfer and any group as to which such persons are party to, do not constitute “interested stockholders” for purposes of this provision.

    

    

    Our authorized but unissued common stock and preferred stock will be available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including
      future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of
      us by means of a proxy contest, tender offer, merger or otherwise.

    

    
      
        

    

    EXCLUSIVE FORUM FOR CERTAIN LAWSUITS

    

    

    Our amended and restated certificate of incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our name, actions against directors, officers and employees
      for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware, except any action (A) as to which the Court of Chancery in the State of Delaware determines that there is an indispensable
      party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive
      jurisdiction of a court or forum other than the Court of Chancery, (C) for which the Court of Chancery does not have subject matter jurisdiction, or (D) any action created by the Exchange Act or any other claim for which the federal courts have
      exclusive jurisdiction. If an action is brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder’s counsel. Unless we consent in writing to the selection of an
      alternative forum, the federal district courts of the United States shall be the exclusive forum for any action arising under the Securities Act. Although we believe this provision will benefit us by providing increased consistency in the application
      of Delaware law in the types of lawsuits to which it applies, a court may determine that this provision is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against our directors and
      officers, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder.

    

    

    
      
        

    

    Our amended and restated certificate of incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law. Section 27 of the Exchange Act
      creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce
      any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.

    

    

    SPECIAL MEETING OF STOCKHOLDERS

    

    

    Our bylaws provide that special meetings of our stockholders may be called only by a majority vote of our board of directors, by either our Chief Executive Officer or our Chairman.

    

    

    ADVANCE NOTICE REQUIREMENTS FOR STOCKHOLDER PROPOSALS AND DIRECTOR NOMINATIONS

    

    

    Our bylaws provide for advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction
      of our board of directors or a committee of our board of directors. In order for any matter to be “properly brought” before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information.
      Generally, to be timely, a stockholder’s notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. Our
      bylaws also specify requirements as to the form and content of a stockholder’s notice. Our bylaws allow the chairman of the meeting at a meeting of the stockholders to adopt rules and regulations for the conduct of meetings, which may have the effect
      of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own
      slate of directors or otherwise attempting to influence or obtain control of us.

    

    

    ACTION BY WRITTEN CONSENT

    

    

    Any action required or permitted to be taken by our common stockholders must be effected by a duly called annual or special meeting of such stockholders and may not be effected by written consent of
      the stockholders other than with respect to our Class B common stock.

    

    

    CLASS B COMMON STOCK CONSENT RIGHT

    

    

    For so long as any shares of Class B common stock remain outstanding, we may not, without the prior vote or written consent of the holders of a majority of the shares of Class B common stock then
      outstanding, voting separately as a single class, amend, alter or repeal any provision of our amended and restated certificate of incorporation, whether by merger, consolidation or otherwise, if such amendment, alteration or repeal would alter or
      change the powers, preferences or relative, participating, optional or other or special rights of the Class B common stock. Any action required or permitted to be taken at any meeting of the holders of Class B common stock may be taken without a
      meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of the outstanding Class B common stock having not less than the minimum number of votes that
      would be necessary to authorize or take such action at a meeting at which all shares of Class B common stock were present and voted.

    

    

    LISTING OF SECURITIES

    

    

    Our units, Class A common stock and warrants are listed on Nasdaq under the symbols “HCARU,” “HCAR” and “HCARW,” respectively.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]